DE602004005392D1 - Biologisch stabile flüssige Zusammensetzung von FVIII, vWF oder FVIII/vWF-Komplex menschlichen Ursprungs - Google Patents

Biologisch stabile flüssige Zusammensetzung von FVIII, vWF oder FVIII/vWF-Komplex menschlichen Ursprungs

Info

Publication number
DE602004005392D1
DE602004005392D1 DE602004005392T DE602004005392T DE602004005392D1 DE 602004005392 D1 DE602004005392 D1 DE 602004005392D1 DE 602004005392 T DE602004005392 T DE 602004005392T DE 602004005392 T DE602004005392 T DE 602004005392T DE 602004005392 D1 DE602004005392 D1 DE 602004005392D1
Authority
DE
Germany
Prior art keywords
fviii
vwf
liquid composition
human origin
stable liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004005392T
Other languages
English (en)
Other versions
DE602004005392T2 (de
Inventor
Gamon Salvador Grancha
Nieto Juan Ignacio Jorquera
Debart Pere Ristol
Riera Marta Massot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols SA filed Critical Grifols SA
Publication of DE602004005392D1 publication Critical patent/DE602004005392D1/de
Application granted granted Critical
Publication of DE602004005392T2 publication Critical patent/DE602004005392T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE602004005392T 2003-10-03 2004-09-24 Biologisch stabile flüssige Zusammensetzung von FVIII, vWF oder FVIII/vWF-Komplex menschlichen Ursprungs Active DE602004005392T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302298A ES2229931B1 (es) 2003-10-03 2003-10-03 Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
ES200302298 2003-10-03

Publications (2)

Publication Number Publication Date
DE602004005392D1 true DE602004005392D1 (de) 2007-05-03
DE602004005392T2 DE602004005392T2 (de) 2007-12-06

Family

ID=34307115

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004005392T Active DE602004005392T2 (de) 2003-10-03 2004-09-24 Biologisch stabile flüssige Zusammensetzung von FVIII, vWF oder FVIII/vWF-Komplex menschlichen Ursprungs

Country Status (13)

Country Link
US (1) US20050074866A1 (de)
EP (1) EP1522312B1 (de)
JP (1) JP4388875B2 (de)
AR (1) AR047756A1 (de)
AT (1) ATE357245T1 (de)
CA (1) CA2481593C (de)
DE (1) DE602004005392T2 (de)
ES (2) ES2229931B1 (de)
HK (1) HK1075406A1 (de)
MX (1) MXPA04009246A (de)
PL (1) PL1522312T3 (de)
PT (1) PT1522312E (de)
UY (1) UY28531A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660531A2 (de) * 2003-08-05 2006-05-31 Novo Nordisk A/S Neue insulinderivate
EP1969004B1 (de) 2005-12-28 2011-08-10 Novo Nordisk A/S Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN101952016A (zh) 2007-12-28 2011-01-19 巴克斯特国际公司 重组vwf配方
TWI670072B (zh) 2008-10-21 2019-09-01 美商巴克斯歐塔公司 凍乾的重組ｖｗｆ調配物
WO2010049488A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
DK3066119T3 (en) * 2013-11-08 2018-11-12 Csl Ltd NEW PROCEDURE FOR CONCENTRATION OF THE VON WILLEBRAND FACTOR OR COMPLEXES OF IT
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP4322918A1 (de) 2021-04-13 2024-02-21 Grifols Worldwide Operations Limited Flüssige zusammensetzung mit faktor viii oder faktor viii/von willebrand faktor komplex
AU2022326188A1 (en) * 2021-08-11 2024-02-22 Grifols Worldwide Operations Limited Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359463A (en) * 1980-11-26 1982-11-16 Rock Gail A Stabilization of Factor VIII activity in whole blood or blood plasma
JPS59116228A (ja) * 1982-12-24 1984-07-05 Green Cross Corp:The 血液凝固第８因子脂肪小体製剤の製法
AT379510B (de) * 1983-05-20 1986-01-27 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
CA2378751C (en) * 1999-07-13 2012-11-06 Biovitrum Ab Stable factor viii compositions

Also Published As

Publication number Publication date
HK1075406A1 (en) 2005-12-16
UY28531A1 (es) 2005-03-31
MXPA04009246A (es) 2005-04-06
ES2280924T3 (es) 2007-09-16
ES2229931A1 (es) 2005-04-16
EP1522312A1 (de) 2005-04-13
AR047756A1 (es) 2006-02-22
PL1522312T3 (pl) 2007-08-31
CA2481593A1 (en) 2005-04-03
JP2005112855A (ja) 2005-04-28
ATE357245T1 (de) 2007-04-15
PT1522312E (pt) 2007-06-19
CA2481593C (en) 2009-10-20
JP4388875B2 (ja) 2009-12-24
US20050074866A1 (en) 2005-04-07
EP1522312B1 (de) 2007-03-21
DE602004005392T2 (de) 2007-12-06
ES2229931B1 (es) 2006-01-16

Similar Documents

Publication Publication Date Title
HK1075406A1 (en) Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin
DK1440148T3 (da) Keratinocytter anvendelige som biologisk aktive substanser i behandling af sår
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
DE60317799D1 (de) Antimikrobielle zusammensetzung und anwendungsverfahren
IL181689A0 (en) Aptamers to von willebrand factor and pharmaceutical compositions containing the same
ATE521334T1 (de) Schweisshemmende oder desodorierende zusammensetzung
DE60325255D1 (de) Duftzusammensetzung
DE60224718D1 (de) System zur hautpflege von benutzern von absorbierenden artikeln
DE602004005753D1 (de) Kombinationen von harzzusammensetzungen und verwendungsverfahren dafür
ATE324586T1 (de) Nitrit-stabilisierte zusammensetzungen von tetrazolium-reagenz und methoden derer nutzung
DE602005027308D1 (de) Stabile salze von olanzapin
ATE336169T1 (de) Verwendung von fettalkoholethoxylaten als penetrationsförderer
DE60304102D1 (de) Hautreinigungszusammensetzung
DE60323947D1 (de) Co-perlchen von dha und rosmarin
DE50304776D1 (de) Bohrlochbehandlungsmittel mit niedrig-toxischer ölphase
ATE380813T1 (de) Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
DE50311735D1 (de) Das tissue engineering von knochen
DE60331183D1 (de) Kontrollierte dosierung von chlordioxid oder anderersystemen
DK1572229T3 (da) Stabilt terapeutisk fibrinogen
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
DE60317639D1 (de) Zusammensetzungen enthaltend n-acyl-phosphatidyl-ethanolamin und/oder mischungen von n-acyl-ethanolaminen mit phosphatidinsäuren oder lysophosphatidinsäuren
ATE316101T1 (de) Thrombinspaltbare faktor-x-analoga
ATE415948T1 (de) Geschmacksmaskierte formulierung von clarithromycin
DE60335623D1 (de) Komponenten von absorbierenden wegwerfartikeln mit gedruckten blöcken
MA28846B1 (fr) Composition biologiquement active

Legal Events

Date Code Title Description
8364 No opposition during term of opposition